Profound Medical Corp.

TSX:PRN.TO

Medical - Devices

Healthcare
$9.83 +1.18%

+$0.11 today

Market cap
$360.04M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $5.23High $12.40

Volume 0.00M

Average 0.01M

PRN.TO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Profound Medical Corp.TSX: PRN.TO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $1.48M rose 92.8% year over year, ahead of the +43.5% change in trailing-twelve-month cost of revenue. Sequentially, it fell 26.6% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Cost of revenue amounted to 29.2% of revenue in FY2025, down 4.9 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +92.8% holds above the trailing-twelve-month pace of +43.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.48M-26.6% QoQ
Last fiscal yearDec 2025
$4.79M+31.4% YoY
LTMMar 2026
$5.43M+43.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+92.8%——
1 year+31.4%——
3-year CAGR+9.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
4.79M USD
Year-over-year change
+31.4%
4-year CAGR
+5.1%

Cost of Revenue vs competitors

How PRN.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +43.5% is the 3rd highest of 6, against a peer median of +37.3%.
  • Cost of revenue amounts to 29.0% of revenue for PRN.TO, versus a peer median of 53.8%.
PRN.TO Competitors
Cost of Revenue for PRN.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRRX.TOCareRx CorporationLTM Mar 2026CA$275.44M CAD+6.6%+0.7%73.5%
DR.TOMedical Facilities CorporationLTM Mar 2026$168.32M USD+61.4%+3.7%55.1%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$83.17M CAD+37.3%-6.0%52.5%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$21.35M USD+122.0%+86.8%38.3%
PRN.TOProfound Medical Corp.LTM Mar 2026$5.43M USD+43.5%+9.4%29.0%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$281.1K USD+30.3%+7.8%—
Peer median (excluding PRN.TO) —+37.3%+3.7%53.8%

Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.87M6.68M7.2M10.68M16.38M
Cost of Revenue3.92M3.66M2.82M3.64M4.79M
Gross Profit2.95M3.02M4.38M7.04M11.59M
Gross Margin43.0%45.2%60.9%65.9%70.8%
Research & Development15.28M14.69M14.38M16.97M20.96M
Selling, General & Admin17.97M17.93M18.62M23.13M32.61M
Operating Expenses33.24M32.62M33M40.1M53.57M
Depreciation & Amortization1.88M1.6M929K936K569.8K
EBITDA(28.65M)(26.6M)(27M)(32.13M)(41.41M)
EBITDA Margin-416.8%-398.2%-375.0%-300.8%-252.8%
Operating Income(30.29M)(29.6M)(28.62M)(33.06M)(41.98M)
Operating Margin-440.7%-443.1%-397.5%-309.6%-256.3%
Interest Income205K1.06M1.64M1.44M1.09M
Interest Expense67K168.82K770K00
Other Income / Expenses(303K)1.22M200K5.24M(1.08M)
Income Before Tax(30.59M)(28.38M)(28.7M)(27.82M)(43.06M)
Pre-Tax Margin-445.1%-424.8%-398.6%-260.5%-262.9%
Income Tax Expense105K287K(128K)(2K)256.41K
Net Income(30.7M)(28.67M)(28.57M)(27.82M)(43.32M)
Net Margin-446.7%-429.1%-396.8%-260.4%-264.4%
EPS (Basic)(1.50)(1.38)(1.35)(1.12)(1.43)
EPS (Diluted)(1.50)(1.38)(1.35)(1.12)(1.43)
Weighted Avg Shares20.46M20.77M21.18M24.77M30.23M
Weighted Avg Shares (Diluted)20.47M20.77M21.18M24.77M30.23M

Profound Medical Corp.

TSX:PRN.TO

Intrinsic Alpha fair value

Locked

Current Price

$9.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.